The Inperia Advance Post-Market Retrospective Study

Study Overview
=================
Brief Summary
-----------------
The Inperia Advance Carbostent™ is a CE-marked infra-popliteal stent for treatment of infra-popliteal artery stenosis. The aim of this post-market retrospective study protocl P32203 is to collect clinical data of patients treated with Inperia Advance for the treatment of infra-popliteal artery stenosis in routine clinical practice. In order to obtain long-term follow-up data, the data collection will be limited to patients that have been treated with the device at least 12 months prior to the study start.

Detailed Description
-----------------
The objective of this post-market study is to systematically collect retrospective clinical data on the implantable medical device Inperia Advance in the daily clinical practice in an unselected population treated within the intended use. Data will be collected via medical chart review in anonymous form to assess the safety and efficacy of Inperia Adavance. The Inperia Advance Carbostent™ is a CE-marked infra-popliteal stent for treatment of infra-popliteal artery stenosis.

Official Title
-----------------
Inperia Advance Carbostent™ for Infra-popliteal Artery Stenosis. Evaluation of Safety and Performance in Everyday Clinical Practice: The Inperia Advance Post-Market Retrospective Study

Conditions
-----------------
Peripheral Arterial Disease

Intervention / Treatment
-----------------
* Device: Inperia Advance


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient has been implanted with at least one Inperia Advance device according to the indications described in the Instructions for Use (IFU). Study device implantation date is at least one year (12 months) prior to the starting date of the retrospective anonymous data collection. Exclusion Criteria: Patients treated less than 12 months prior to study start

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Inperia Advance|Patients with infra-popliteal artery stenosis implanted with at least one Inperia Advance device|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of Major Adverse Events (MAE) | Composite endpoint of all causes of death, unplanned target limb major amputation and/or clinically indicated target lesion revascularization (TLR) | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Primary patency | Primary patency is defined as absence of clinically-driven target lesion revascularization or binary restenosis. Binary restenosis is defined as a peak systolic velocity ratio (PSVR) >2.4 (Duplex Ultrasound evaluation) | 6 months and 12 months | 
| Limb-salvage rate (LSR) | Limb-salvage rate (LSR) is defined as rate of patients free from major amputation. Major amputation is defined as at or above ankle, as opposed to minor amputation being at or below metatarsus preserving functionality of foot | 6 months and 12 months | 
| Secondary patency | Patency following successful target lesion revascularization (TLR) | 6 months and 12 months or latest patency data available | 
| Death | Death within 30 days of the index procedure | 30 days | 
| Clinically driven Target Lesion Revascularization | Clinically driven Target Lesion Revascularization | 6 months and 12 months | 
| Target limb ischemia | Target limb ischemia requiring surgical intervention or surgical repair of target vessel rate | 6 months and 12 months | 
| Rutherford category measurement | Rutherford category measurement | pretreatment, 6 months and 12 months | 
| Evaluation of Serious Adverse Events (SAEs) | Evaluation of Serious Adverse Events (SAEs) | 6 months and 12 months | 
| Acute success (device and procedural) within discharge | Clinical device success defined as successful delivery and deployment of the stent(s) at the intended target lesion (this includes successful delivery and deployment of multiple stents) and final residual stenosis of the target lesion minor or equal to 30%, assessed by visual estimation and clinical device success without the occurrence of MAE during the hospital stay | 24/72 hours |